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Abstract
Objective: To obtain consensus on management criteria for symptomatic patients with chronic venous disease
(CVD; C2–C6) and superficial venous reflux.
Method:We used a Delphi method by means of 36 statements sent by email to experts in the field of phlebology across
the world over the course of three rounds. The statements addressed criteria for different venous treatments in patients
with different characteristics (e.g. extensive comorbidities, morbid obesity and peripheral arterial disease). If at least 70%
of the ratings for a specific statement were between 6 and 9 (agreement) or between 1 and 3 (disagreement), experts’
consensus was reached.
Results: Twenty-five experts were invited to participate, of whom 24 accepted and completed all three rounds.
Consensus was reached in 25/32 statements (78%). However, several statements addressing UGFS, single phlebectomies,
patients with extensive comorbidities and morbid obesity remained equivocal.
Conclusion: Considerable consensus was reached within a group of experts but also some gaps in available research
were highlighted.
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Introduction
Over the past decades, numerous eﬀective treatments
have been developed for patients with chronic
venous disease (CVD). The increased availability of
diﬀerent treatment options has made the management
of CVD more challenging. It has resulted in a large
worldwide variation in management preferences for
treating patients with CVD.1,2 Management strategies
are not only based on evidence from the literature but
also on the physician’s own experience, availability
(and costs) of the equipment and on national healthcare
reimbursement systems. However, in clinical practice,
management decisions should ideally be inﬂuenced
mainly by a combination of patient characteristics,
clinical ﬁndings and results of duplex ultrasound
(DUS).1,3,4
Although there are several well-established national
and international guidelines,5–8 their recommendations
only focus on the treatment of a diseased population
rather than an individual patient.9 Appropriate tools
for management strategies incorporating the speciﬁc
characteristics of an individual patient, as well as
the clinical and DUS ﬁndings, are lacking in current
clinical guidelines.5–8 To bridge the gap between cur-
rent clinical guidelines and individualized care, expert
opinion methods such as a Delphi consensus10 are
desired.
The aim of the present study was to achieve an
international Delphi-based consensus on management
criteria for patients presenting with venous symptoms,
clinical signs of CVD, and superﬁcial venous reﬂux con-
ﬁrmed by DUS.
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Experts were selected from a group of physicians who
already participated in our recently published world-
wide survey on management strategies in patients
with CVD (C2–C6).1 Only those with at least one sci-
entiﬁc publication in the ﬁeld of phlebology in a peer-
reviewed journal and at least 10 years of experience in
treating patients with CVD were eligible for the present
study. They had to be performing ultrasound-guided
foam sclerotherapy (UGFS), endovenous thermal abla-
tion (EVTA) and phlebectomies themselves. Two inves-
tigators (SKvdV and MGRDM) selected the expert
panel. For this selection, they aimed at having a
reasonable distribution between diﬀerent specialties
(vascular or general surgeons, dermatologists, angiolo-
gists, phlebologists) and continent or country of clinical
practice. Based on the selection criteria, 25 eligible
experts were invited by email. They were asked to
judge on several statements in view of obtaining con-
sensus over the course of three rounds, according to the
Delphi method between March 2015 and November
2015 (Figure 1). In case of non-responding, the inves-
tigators sent two email reminders in each round.
Informed consent was not performed because no
patients were involved in this study.
Delphi consensus procedure
The authors formulated the statements, using results
from a worldwide survey regarding management stra-
tegies in patients with great saphenous vein (GSV) and
tributary reﬂux.1 The ﬁrst round contained 30 state-
ments addressing criteria for endovenous ablation
(EVA) of the reﬂuxing saphenous trunk (ST), including
both thermal and non-thermal ablation techniques
(mainly for simplicity), UGFS, high ligation and strip-
ping (HL/S), single phlebectomies without treatment of
the reﬂuxing saphenous trunk referred to as ‘ambula-
tory selective varicose ablation under local anaesthesia’
(ASVAL)11 and non-interventional measures (veno-
tonic drugs and medical elastic compression stockings
(MECS)). The statements contained scenarios with dif-
ferent patient characteristics, clinical class (C2–C6,
according to the CEAP classiﬁcation12) and DUS
Figure 1. Selection of participants for the Delphi consensus.
*Eligibility criteria: performing varicose vein treatments for at least five years and familiar with the use of several currently used
varicose veins techniques including, phlebectomies, one of the techniques for endovenous thermal ablation, and ultrasound-guided
foam sclerotherapy. They were also allowed to participate if they did not perform EVTA themselves, but delegated this to a colleague
when indicated. The same was true for high ligation and stripping.
**Eligibility criteria: at least one scientific publication in a phlebologic peer-reviewed journal, at least ten years of experience in treating
phlebologic patients and performing ultrasound-guided foam sclerotherapy, endovenous thermal ablation and phlebectomies
themselves.
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ﬁndings in patients with CVD of the lower limbs and
superﬁcial venous reﬂux in a ST. The terminology used
for the statements is summarized in Table 1.
Participants were asked to anonymously rate each
statement on a 9-point scale, by ticking boxes with
marks between 1 and 9, where a score of 1 denoted
complete disagreement and a score of 9 indicating full
agreement (Figure 2). If at least 70% of the ratings for a
speciﬁc statement were between 7 and 9, it was con-
cluded experts consented on agreeing with the state-
ment. Vice versa, if 70% were between 1 and 3, it
was concluded they consented on disagreeing with the
statement. This cut-oﬀ level was based on previous lit-
erature.13,14 Any other distribution of ratings was
valued ‘equivocal’. Participants also had the opportun-
ity to add a comment in the ‘remark(s)’ box accom-
panying each statement. All this information was used
for preparing the subsequent round of the Delphi
consensus.
In the second round, experts received a full report of
the ﬁrst round, including a compilation of ratings for
all statements of the ﬁrst round, and all the remarks of
their colleagues, provided anonymously. Then, they
were asked to rate again those statements that had
remained equivocal in the ﬁrst round. Statements
were reformulated and new statements were added
based on the remarks of the experts in the previous
round. For instance, in the ﬁrst round, we had included
older age as a patient characteristic, which might inﬂu-
ence management. However, participating experts sug-
gested age was not the main factor, but rather extensive
comorbidities, and therefore the statement was adapted
as such. Eventually, the second round contained 18
statements. In the second round, we also attached a
summary of the present literature regarding each
statement.
The same procedure was followed for the third
(and last) round, which contained only nine statements
to be rated. Again, participating experts could consider
the results of the second round and the remarks of their
colleagues.
In case of one or more missing items, the expert was
contacted by email to retrieve the missing answer.
Results
Experts
In total, 24 out of 25 contacted experts accepted to
participate: 15 vascular surgeons, two general surgeons,
four dermatologists, two angiologists and one
phlebologist from Europe (17/25), Australia (1/25),
Table 1. Definition of terminology used for the statements of the Delphi consensus.
Venous symptoms: ache, pain, heaviness, tightness, feeling of swelling, nocturnal cramps, itching
C disease: clinical class according to the CEAP classification12: C2: varicose veins; C3: edema; C4: skin
changes (pigmentation, eczema, atrophie blanche, lipodermatosclerosis); C5: healed venous
ulcer; C6: open venous ulcer
Saphenous trunk: great saphenous vein, anterior accessory saphenous vein, posterior accessory saphenous
vein, Giacomini vein, small saphenous vein
Varicose tributaries: visible or palpable varicose veins in the subcutis
Reflux in a saphenous trunk: abnormally reversed flow in a saphenous trunk, during> 500ms at calf compression-release
or Valsalva (the latter only for the SFJ) involving the terminal or preterminal valve of the SFJ
or the SPJ
Terminal valve reflux: reflux at the junction of the SFJ or SPJ
Segmental reflux: reflux limited to a segment of a saphenous trunk, not involving the SFJ or SPJ
Saphenous diameter: diameter measured in a tubular part of the refluxing vein segment, about 15 cm from the
junction in standing position
Focal dilatation: localized dilatation of the saphenous trunk less than 1.5–3 times the saphenous diameter
above or below
Aneurysm: dilatation of the saphenous vein more than three times the saphenous diameter above or
below, or more than 20mm (close to the SFJ or SPJ)
Morbid obesity: BMI> 40 kg/m2 or BMI> 35 kg/m2 and experiencing obesity-related health conditions
Severe peripheral arterial
disease: ankle brachial index< 0.6
Bridging: oral anticoagulation is interrupted with bridging anticoagulation, using either heparin or low-
molecular weight heparin, administered during the sub-therapeutic window
SFJ: saphenofemoral junction; SPJ: saphenopopliteal junction; BMI: body mass index.
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North-America (4/25) and Central- or South-America
(3/25). Experts were working in private practice (13/25),
general hospital (4/25) or university hospital (7/25).
All these experts completed the ﬁrst, second and
third Delphi round (25/25). The majority of experts
(16/25) had over 20 years of experience in treating
patients with CVD.
Delphi consensus
After three rounds, consensus was reached in 25 out of
32 statements (78%; Table 2). All statements regarding
indications for treatment with thermal or non-thermal
EVA vs. treatment with HL/S reached high (>79%)
consensus in favor of EVA, except for venous aneur-
ysms. Of note, 96% of the experts agreed on that high
ligation should not be added to EVA treatment. Similar
level of agreement was reported about the use of MECS
as preferred strategy in those patients with C4–C6 dis-
ease and reﬂux in an ST, who are not willing or contra-
indicated to undergo any intervention.
The experts’ opinion on several statements remained
equivocal after three rounds. This was the case for
statements addressing diﬀerent indications for UGFS,
ASVAL, extensive comorbidities and morbid obesity.
The experts stated that it depended on the type and
extent of the patient’s comorbidities and therefore no
deﬁnitive conclusion on preferred management could
be made. Regarding morbid obesity, the experts
would deﬁnitely prefer EVA over HL/S, but there was
no agreement on limiting treatment to those patients
with skin changes (C4–C6). Moreover, based on their
experience, the participants were convinced that advis-
ing weight reduction unfortunately was unsuccessful in
the majority of obese patients.
Throughout the diﬀerent rounds of the Delphi con-
sensus, three statements were removed, two because of
redundancy after reformulating other statements and
one because of lack of relevance following the experts’
remarks (Supplementary Table 1).
Discussion
The present study showed that considerable consensus
could be reached within a group of selected experts in
the ﬁeld of treatment of superﬁcial venous disease, by
means of a Delphi consensus procedure. This may help
physicians to make supported and individualized
choices for their patients with CVD (C2–C6).
Not surprisingly, experts’ recommendations regard-
ing EVA were in line with current guidelines on the care
of patients with varicose veins and associated CVD.5–8
EVA was considered the preferred treatment for most
symptomatic patients with CVD (C2–C6) and a reﬂux-
ing ST> 4mm in diameter. The expert panel did not
recommend an alternative treatment for speciﬁc DUS
ﬁndings such as terminal valve reﬂux, a large (>10mm)
ST diameter or the presence of one or more focal
dilatations of the ST (Table 2). EVA has now glo-
bally become the preferred treatment for ST reﬂux as
is reﬂected in our results. Although EVA (thermal or
non-thermal) has largely replaced HL/S in many coun-
tries, it should be acknowledged that, whenever equip-
ment for EVA is not available, HL/S (ideally using
tumescent anesthesia, in agreement with recent guide-
lines6) remains a valuable treatment option. While
patient-reported outcomes favor EVTA, long-term eﬃ-
cacy of HL/S and EVTA are very similar.15,16
UGFS is usually considered as the second best
option of the minimally invasive treatments for abol-
ishing ST reﬂux.5–8 In the present consensus approach,
the experts considered UGFS to be just ‘a’ treatment
option if ST diameter is 4mm, and only agreed on
categorizing it ‘a valuable treatment option’ for ST’s
with small diameters< 4mm. This discrepancy illus-
trates that ST diameter may be used as a relevant cri-
terion to distinguish between diﬀerent treatment
options,1 which is in line with the European guidelines
forsclerotherapy.17
ASVAL is not yet a worldwide-accepted strategy,
and this was reﬂected in the Delphi consensus.
Contrarily to what the investigators had been suggest-
ing, the experts could not agree on particular criteria
for implementing ASVAL so far. This is somehow to be
expected as only 42% of the experts had ever used
ASVAL in their clinical practice (data not shown)
and the evidence on the subject is still limited.11,18,19
Future research should point out whether ASVAL
can be applied in all patients with varicose veins or in
a selected varicose vein population only.
At the end of the ﬁrst round of the Delphi consensus,
older age appeared to be less relevant than we initially
had hypothesized and it was therefore converted into
extensive comorbidities as suggested by the participants
from the second round onwards. Indeed, clinical studies
demonstrated that the feasibility and safety of EVTA
and tolerability of UGFS were similar in patients older
or younger than 75 years.20,21 In contrast, studies
regarding venous treatments in patients with (extensive)
comorbidities are completely lacking. Although the
Figure 2. Example of a statement showing consensus on
agreement (84% of marks between 7 and 9).
HL/S: high ligation and stripping.
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Table 2. Results of Delphi consensus.
Delphi rounds
Statements 1 2 3
EVA vs. HL/S
Nowadays, with the availability of endovenous treatments, HL/S is only rarely indicated. 84%
In case of saphenous reflux, EVA is indicated rather than HL/S, even if there is C4–C6 disease. 83%
In patients with venous symptoms and reflux in a saphenous trunk, EVA is indicated rather than
HL/S, even in the presence of TV reflux.
83%
In patients with venous symptoms and reflux in a saphenous trunk, EVA is indicated rather than
HL/S, even in the presence of a large (>10mm) saphenous diameter.
79%
In patients with venous symptoms and reflux in a saphenous trunk, EVA is indicated rather than
HL/S, even in the presence of one or more focal dilatations.
79%
Presence of a venous aneurysm (>20mm) within 2 cm from the SFJ or SPJ is an indication for
HL/S rather than EVA.
HL should not be added to patients being treated with EVA. 96%
UGFS
In the presence of C4-C6 disease in patients with reflux in a saphenous trunk> 4mm in diameter,
UGFS is a treatment option.a,b
93%
In the presence of C4-C6 disease in patients with reflux in a saphenous trunk< 4mm in diameter,
UGFS is a valuable treatment option.*
80%
In the presence of C4-C6 disease in patients with reflux in a saphenous trunk< 4mm in diameter
and refluxing tributaries in a diseased skin area, UGFS of tributaries is preferred rather than
phlebectomies.
c 87%
In the presence of C4-C6 disease in patients with reflux in a saphenous trunk< 4mm in diameter
and refluxing tributaries, UGFS and phlebectomies of tributaries at a distance from the
diseased skin area, are both valuable treatment options.
c 92%
In patients with venous symptoms and reflux in a saphenous trunk, UGFS (without tumescent
anesthesia) is a valuable treatment option, even in the presence of a large (>10mm)
saphenous diameter.a
75%
In patients with venous symptoms and reflux in a saphenous trunk vein> 10mm in diameter,
where ablation is indicated, EVA is preferred rather than UGFS.
92%
If you have decided to ablate the saphenous trunk, in the presence of C2-C3 disease in patients
with venous symptoms and reflux in a saphenous trunk vein< 4mm in diameter, UGFS is
preferred rather than EVA.a,b
EVA
In the presence of C4–C6 disease in patients with reflux in a saphenous trunk< 4mm in
diameter, EVA is a valuable treatment option.
c 71%
ASVAL
In the presence of C2–C3 disease in patients with venous symptoms, segmental reflux of a
saphenous trunk< 4mm in diameter and large refluxing tributaries, preservation of the
saphenous trunk is indicated rather than its ablation.a,b
ASVAL is not indicated in case of reflux in a saphenous trunk and C4-C6 disease. 83%
Non-interventional measure
In patients with venous symptoms, C2–C3 disease and reflux in a saphenous trunk and who are
not willing to undergo any intervention or who are unfit for intervention because of extensive
comorbidities, MECS should be considered.
88%
In patients with venous symptoms, C2–C3 disease and reflux in a saphenous trunk and who are
not willing to undergo any intervention or who are unfit for intervention because of extensive
comorbidities, venotonic drugs should be considered.
79%
In patients with C4–C6 disease and reflux in a saphenous trunk and who are not willing to
undergo any intervention or who are unfit for intervention because of extensive
comorbidities, MECS are indicated.
96%
(continued)
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investigators thought that minimizing the extent of pro-
cedures in patients with comorbidities and/or morbid
obesity would be good clinical practice, experts did not
reach consensus on this issue. This lack of consensus
could partly be explained by the fact that many diﬀer-
ent combinations of comorbidities can be thought of in
these cases and the extent of comorbidities was not
deﬁned in the statements. The experts seemed to be
more unanimous regarding strategies in patients
under chronic anticoagulant treatment and those with
severe peripheral arterial disease.
Although we found considerable consensus about
treatment strategies in diﬀerent clinical classes and
DUS ﬁndings, statements addressing patients’ charac-
teristics remained largely equivocal in the Delphi con-
sensus. This clearly highlights the lack of knowledge in
the ﬁeld of personalized medicine and implies that more
research regarding patient characteristics, and how
these are inﬂuencing treatment outcomes, is needed.
In this way, future guidelines may include more tools
for proper stratiﬁcation of patients with CVD.
Obviously, when deﬁning individualized treatment
Table 2. Continued
Delphi rounds
Statements 1 2 3
Comorbidities
In patients with venous symptoms in addition to extensive comorbidities and reflux in a
saphenous trunk, UGFS is indicated rather than EVA.a
In patients with venous symptoms in addition to extensive comorbidities and reflux in a
saphenous trunk, EVA or UGFS should only be considered in case of C4–C6 disease.a
Morbid obesity
In patients with venous symptoms, reflux in a saphenous trunk and morbid obesity, EVA or UGFS
are indicated rather than HL/S.
87%
In patients with venous symptoms, reflux in a saphenous trunk and morbid obesity, treatment
should only be considered in case of C4–C6 disease.b
In patients with venous symptoms, morbid obesity and reflux in a saphenous trunk, weight
reduction is advised prior to any venous treatment.b
c
Anticoagulation
In patients with venous symptoms, reflux in a saphenous trunk and who are on chronic
anticoagulants, EVA is indicated rather than HL/S.
92%
In patients with venous symptoms, reflux in a saphenous trunk< 4mm diameter and who are on
chronic anticoagulants, UGFS is indicated rather than HL/S.a
91%
In patients with venous symptoms, reflux in a saphenous trunk and who are on chronic
anticoagulants, EVA can be performed without bridging.
87%
In patients with venous symptoms, reflux in a saphenous trunk and who are on chronic
anticoagulants, UGFS can be performed without bridging.
88%
In patients with venous symptoms, who are on chronic anticoagulants and who are scheduled for
extensive phlebectomies, temporary discontinuation and anticoagulant treatment bridging is
indicated.b
88%
Severe peripheral arterial disease
In patients with C2–C3 disease, reflux in a saphenous trunk and severe peripheral arterial
disease, it is preferable not to ablate the saphenous vein by means of EVA, UGFS or HL/S.
79%
In patients with C4–C6 disease, reflux in a saphenous trunk and severe peripheral arterial
disease, EVA or UGFS of the refluxing saphenous vein may be considered.
71%
EVA: endovenous ablation (including thermal and non-thermal non-tumescent techniques, excluding UGFS); HL/S: high ligation with stripping;
SFJ: saphenofemoral junction; SPJ: saphenopopliteal junction; UGFS: ultrasound-guided foam sclerotherapy; ASVAL: ‘ambulatory selective varicose
ablation under local anaesthesia’ (¼ single phlebectomies without treating the saphenous trunk); MECS: medical elastic compression stockings.
Consensus on agreeing with the statement.
Consensus on disagreeing with the statement.
Equivocal (no complete agreement nor disagreement).
aStatement was reformulated after first round.
bStatement was reformulated after second round.
cStatement was added after remarks of experts in the first round.
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strategies in patients with CVD, physicians should also
consider patient’s preference, as well as the impact of
the disease on Health-Related Quality of Life
(HRQoL), the estimated risk of deterioration of CVD
and local healthcare resources.
Limitations
This study has several limitations. The statements may
have been incomplete, but this was minimized because
they were based on a prior worldwide survey among
211 specialists in CVD.5 Also, this study focused on
the treatment of patients with venous symptoms, clin-
ical signs of CVD, and superﬁcial venous reﬂux in the
ST and tributaries, and therefore our results are not
generalizable to all patients with CVD (e.g. patients
with a pathological perforating vein nearby a venous
ulcer or patients with groin recurrence). Selection bias
among the eligible experts might have occurred because
the majority of the participants were working in
Western Europe. However, the response rate was
almost perfect. In the absence of clear guidelines for a
Delphi consensus, we chose the cut-oﬀ value of 70% as
acceptable, because of the relatively mild impact of
CVD on HRQoL, contrarily to decision-making in
more life-threatening diseases in which a higher cut-
oﬀ may be desired. In addition, there is no standard
method for calculating sample sizes for a Delphi study,
but there is evidence that expert panels of 20 can reach
a valid consensus.22
Conclusion
In conclusion, in the present investigation about
management strategies in patients with symptoms
and signs of CVD and superﬁcial venous reﬂux, the
experts agreed on most of the strategies and their opin-
ions largely reﬂected international guidelines.
Nevertheless, it appeared to be more diﬃcult to reach
consensus on the inﬂuence of certain patient-related
characteristics. More research is needed in the ﬁeld
of personalized medicine, in order to further optimize
phlebologic care for all our patients presenting
with CVD.
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